Schroder Investment Management Group Has $210.35 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Schroder Investment Management Group increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,286,141 shares of the biopharmaceutical company’s stock after buying an additional 282,787 shares during the period. Schroder Investment Management Group owned 0.18% of Gilead Sciences worth $210,348,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. HHM Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new position in Gilead Sciences during the fourth quarter worth $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences during the fourth quarter valued at about $29,000. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences in the fourth quarter worth about $31,000. Finally, Stephens Consulting LLC boosted its stake in shares of Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 260 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.6 %

GILD opened at $111.79 on Friday. The firm’s fifty day moving average is $105.48 and its two-hundred day moving average is $94.90. The firm has a market cap of $139.22 billion, a PE ratio of 302.14, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.83%. The ex-dividend date of this dividend was Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is 854.05%.

Analyst Ratings Changes

GILD has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Bank of America increased their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. The Goldman Sachs Group boosted their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $105.12.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 302,785 shares of company stock valued at $30,503,250 over the last quarter. Corporate insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.